vs
中国太平保险控股（IGIC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是中国太平保险控股的1.5倍（$622.0M vs $403.8M），Royalty Pharma plc净利率更高（34.4% vs 26.0%，领先8.4%）
中国太平保险控股有限公司（前身为中国保险国际控股有限公司）是一家中国保险集团，虽在香港注册成立，但背靠中国中央政府，属红筹企业，在保险行业拥有深厚的资源积累与市场影响力。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
IGIC vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.5倍
$403.8M
净利率更高
RPRX
高出8.4%
26.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $403.8M | $622.0M |
| 净利润 | $105.1M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | — | 62.4% |
| 净利率 | 26.0% | 34.4% |
| 营收同比 | — | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | $2.31 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IGICRPRX
| Q4 25 | — | $622.0M | ||
| Q3 25 | $403.8M | $609.3M | ||
| Q2 25 | $261.9M | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | — | $593.6M | ||
| Q3 24 | $369.6M | $564.7M | ||
| Q2 24 | $265.8M | $537.3M | ||
| Q1 24 | — | $568.0M |
净利润IGICRPRX
| Q4 25 | — | $214.2M | ||
| Q3 25 | $105.1M | $288.2M | ||
| Q2 25 | $61.4M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $-134.4M | $544.0M | ||
| Q2 24 | $70.7M | $102.0M | ||
| Q1 24 | — | $4.8M |
营业利润率IGICRPRX
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | 24.2% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | -73.3% | 50.2% | ||
| Q1 24 | — | -13.0% |
净利率IGICRPRX
| Q4 25 | — | 34.4% | ||
| Q3 25 | 26.0% | 47.3% | ||
| Q2 25 | 23.5% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | -36.4% | 96.3% | ||
| Q2 24 | 26.6% | 19.0% | ||
| Q1 24 | — | 0.8% |
每股收益（稀释后）IGICRPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | $2.31 | $0.67 | ||
| Q2 25 | $1.36 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | $1.82 | $1.21 | ||
| Q2 24 | $1.55 | $0.23 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $244.7M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $654.8M | $9.7B |
| 总资产 | $2.0B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资IGICRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | $244.7M | $938.9M | ||
| Q2 25 | $164.8M | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | $219.2M | $950.1M | ||
| Q2 24 | $237.3M | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务IGICRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益IGICRPRX
| Q4 25 | — | $9.7B | ||
| Q3 25 | $654.8M | $9.6B | ||
| Q2 25 | $662.3M | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | — | $10.3B | ||
| Q3 24 | $540.5M | $10.3B | ||
| Q2 24 | $588.2M | $9.8B | ||
| Q1 24 | — | $9.9B |
总资产IGICRPRX
| Q4 25 | — | $19.6B | ||
| Q3 25 | $2.0B | $19.3B | ||
| Q2 25 | $2.1B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | — | $18.2B | ||
| Q3 24 | $1.8B | $18.0B | ||
| Q2 24 | $2.0B | $17.7B | ||
| Q1 24 | — | $16.1B |
负债/权益比IGICRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流IGICRPRX
| Q4 25 | — | $827.1M | ||
| Q3 25 | — | $702.6M | ||
| Q2 25 | $27.2M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | — | $703.6M | ||
| Q2 24 | $120.7M | $658.2M | ||
| Q1 24 | — | $664.6M |
自由现金流IGICRPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $26.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $119.8M | — | ||
| Q1 24 | — | — |
自由现金流率IGICRPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 45.1% | — | ||
| Q1 24 | — | — |
资本支出强度IGICRPRX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | — | — |
现金转化率IGICRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 0.44× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | 1.71× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IGIC
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
